This is not a theoretical product of the future, but a real solution that works today
The care team can review symptoms, outside labs, prior treatment plans, and whether a same-day B12 shot is appropriate before treatment is given
Compared to other treatments, oral semaglutide showed superior efficacy in reducing glycosylated hemoglobin (HbA1c) levels, making it a competitive option for patients who do not achieve desired results with traditional oral medications like sitagliptin and empagliflozin
Not everyone experiences side effects at the same time
The Insurance Prior Authorization Maze For platforms that prescribe brand-name GLP-1s, the primary administrative mechanism is the Prior Authorization (PA) process
For those with hypermobility and EDS specifically, Id flag the following as the minimum due diligence before starting these medications: A thorough GI history and ideally gastric emptying assessment if theres any existing dysmotility Baseline muscle mass measurement (DEXA or similar) given the sarcopenia risk A clear plan for high-protein diet and resistance-based exercise to mitigate muscle loss Baseline bone density if theres any existing concern Consideration of the nutritional picture specific to hypermobility, since these drugs can affect appetite and nutrient absorption A conversation specifically about MCAS if thats a feature of your presentation The medication options for hypermobility and EDS are limited and often unsatisfying, and its entirely understandable why people are looking at something new with genuine curiosity
